* This study aims to investigate whether Coenzyme Q10 supplementation can reduce chemotherapy-induced peripheral neuropathy, fatigue, and pain in women with newly diagnosed breast cancer receiving paclitaxel treatment. The study will also examine the effects of Coenzyme Q10 on biomarkers associated with nerve damage. The main questions it seeks to answer are: * Does Coenzyme Q10 improve patients' quality of life by reducing neuropathy, fatigue, and pain during chemotherapy? * How does Coenzyme Q10 affect serum levels of nerve growth factor, neurofilament light chain, malondialdehyde, and osteopontin during treatment? * Participants will: Receive either Coenzyme Q10 along with standard weekly paclitaxel chemotherapy or paclitaxel alone for twelve weeks. * Complete questionnaires on neuropathy, fatigue, and pain at the end of each chemotherapy cycle. * Provide blood samples at the beginning and end of the study to measure biomarkers of nerve injury.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change from Baseline in Serum Nerve Growth Factor (NGF) Levels
Timeframe: Baseline (1 hour before first cycle) and End of Treatment (1 hour after final cycle, approximately Week 12).
Change from Baseline in Serum Neurofilament Light Chain (NFL) Levels
Timeframe: Baseline (1 hour before first cycle) and End of Treatment (1 hour after final cycle, approximately Week 12).
Change from Baseline in Serum Osteopontin (OPN) Levels
Timeframe: Baseline (1 hour before first cycle) and End of Treatment (1 hour after final cycle, approximately Week 12).
Change from Baseline in Serum Malondialdehyde (MDA) Levels
Timeframe: Baseline (1 hour before first cycle) and End of Treatment (1 hour after final cycle, approximately Week 12).